Ms. Brigitte Nolet at the Industry, Science and Technology Committee

On October 23rd, 2012. See this statement in context.

October 23rd, 2012 / 12:15 p.m.

Director, Government Relations and Health Policy, Specialty Division, Hoffmann-La Roche Limited, Canada's Research-Based Pharmaceutical Companies (Rx&D)

Brigitte Nolet

I think if we look at past results from the $93 million in 1987 to the over $1 billion nvested now, we have seen an increase that is quite linear in relation to changes in the Patent Act and what that has meant for pharmaceutical R and D.

See context to find out what was said next.